PACS — PACS Group, Inc. stock price, charts and financials

NYSE·Healthcare·Medical - Care Facilities·USA

Latest market price

42.12

+0.06+0.14%

Overview Short InterestFilings

PACSQT80PACS Group, Inc.·NYSE

Overview Short InterestFilings

42.12+0.14%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CHE-0.38%$504.06 HIMS+0.36%$27.99 LFST-0.32%$12.57 CON-0.17%$35.47 ENSG-0.58%$173.91 UHS-2.25%$176.69 DVA+0.42%$183.86 FMS+0.59%$22.20

Snapshot

Index	-	P/E	25.22	EPS (ttm)	1.67	Insider Own	-	Shs Outstand	158.34M	Perf Week	-5.90%

Market Cap	6.67B	Forward P/E	16.08	EPS next Y	2.62	Insider Trans	-1.32%	Shs Float	47.80M	Perf Month	-4.84%

Enterprise Value	9.60B	PEG	2.62	EPS next Q	0.57	Inst Own	-	Short Float	2.10%	Perf Quarter	15.11%

Income	269.00M	P/S	1.20	EPS this Y	41.77%	Inst Trans	-	Short Ratio	3.78	Perf Half Y	21.59%

Sales	5.55B	P/B	5.98	EPS next Y	10.63%	ROA	4.76%	Short Interest	3.33M	Perf YTD	9.72%

Book/sh	7.04	P/C	40.66	EPS next 5Y	9.61%	ROE	27.15%	52W High	49.49 -14.89%	Perf Year	275.40%

Cash/sh	1.04	P/FCF	15.55	EPS past 3/5Y	6.85% -	ROIC	6.06%	52W Low	10.31 308.54%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	20.00	Sales past 3/5Y	29.74% -	Gross Margin	19.68%	Volatility	3.74% 3.63%	Perf 5Y	-

Dividend TTM	-	EV/Sales	1.73	EPS Y/Y TTM	339.47%	Oper. Margin	7.39%	ATR (14)	1.74	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	0.91	Sales Y/Y TTM	35.72%	Profit Margin	4.85%	RSI (14)	41.33	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	0.91	EPS Q/Q	13.51%	SMA20	-2.99%	Beta	0.36	Target Price	56.67

Payout	0.00%	Debt/Eq	3.45	Sales Q/Q	9.09%	SMA50	-5.62%	Rel Volume	1.36	Prev Close	42.06

Employees	47,455	LT Debt/Eq	3.45	Earnings	Nov 09	SMA200	9.45%	Avg Volume	870.63K	Price	42.12

IPO Date	Apr 11, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.43% 1.00%	Net Debt/EBITDA	6.43	Volume	1,181,363	Change	0.14%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-02-26	Reiterated	Truist Financial	Buy	$52 → $62
Aug-06-26	Reiterated	UBS	Buy	$57 → $60
Jul-08-26	Reiterated	UBS	Buy	$42 → $57
May-18-26	Reiterated	Truist Securities	Buy	$40 → $52
May-13-26	Reiterated	Oppenheimer	Outperform	$40 → $48
Feb-27-26	Reiterated	RBC Capital	Outperform	$47 → $52
Dec-19-25	Reiterated	RBC Capital	Outperform	$33 → $47
Dec-18-25	Resumed	UBS	Buy	$42
Dec-12-25	Reiterated	Truist Financial	Buy	$32 → $40
Nov-20-25	Reiterated	RBC Capital	Outperform	$30 → $33

Latest News· Times ET

Sep-17-26

Sep-17-2612:11AM

Mark Hancock Sells 144,318 Shares of PACS Group (NYSE:PACS) Stockdefenseworld.net

12:11AM

Mark Hancock Sells 155,682 Shares of PACS Group (NYSE:PACS) Stockdefenseworld.net

Sep-16-26

Sep-16-2612:10AM

Jason Hulse Murray Sells 10,529 Shares of PACS Group (NYSE:PACS) Stockdefenseworld.net

Sep-15-26

Sep-15-2608:52AM

Behind The Portfolio: Why Steve Cress Owns This Top-Rated StockSeekingAlpha

Sep-14-26

Sep-14-2605:15AM

PACS Group, Inc. to Present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15, 2026businesswire.com

Sep-11-26

Sep-11-2601:00AM

I Own 9 Of The Top 10 Stocks For H2 2026: Why I'm Staying The CourseSeekingAlpha

Sep-08-26

Sep-08-2608:40AM

PACS Expands Florida Footprint With 32-Facility Acquisitionzacks.com

Sep-04-26

Sep-04-2608:00AM

JP Morgan Maintains Overweight on PACS Group, Raises Price Target to $58Benzinga

Sep-03-26

Sep-03-2611:26PM

Bank of New York Mellon Corp Takes Position in PACS Group, Inc. $PACSdefenseworld.net

Sep-01-26

Sep-01-2602:52PM

PACS Group: The Peer Check Stopped Me From Calling It Cheapseekingalpha.com

12:15PM

PACS Group to Acquire Operations of 32 Facilities Across Florida and Closes on Additional Previously Announced Eduro Facilitiesbusinesswire.com

Aug-28-26

Aug-28-2601:29AM

PACS Group (PACS) Price Target Increased by 14.73% to 60.38Fintel

Aug-25-26

Aug-25-2609:00AM

Allegion Redefines Commercial Access Control with the Schlage XE360™ Series featuring RealSync™ Persistent Wi-Fi Technologygurufocus.com

01:55AM

Zacks Industry Outlook CareDx, BrightSpring and PACSzacks.com

Aug-24-26

Aug-24-2606:26AM

3 Medical Service Stocks Resilient Amid Persistent Workforce Shortagezacks.com

Company

PACS Group, Inc. operates as a holding company, primarily focused on delivering post-acute healthcare services. This encompasses operating various facilities, providing skilled professionals, and offering essential ancillary support. The company further specializes in providing a spectrum of senior living options, encompassing dedicated senior care, assisted living, and independent living residences in select communities. Founded in 2013 by Jason Murray and Mark Hancock, its corporate headquarters are located in Farmington, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	5,551	5,289	4,090	—	—	—
Cost of Goods Sold Incl. D&A	4,458	4,130	3,297	—	—	—
Gross Profit	1,092	1,159	793	—	—	—
Selling, General and Administrative Excl. Other	442	415	344	—	—	—
Research and Development	0	0	0	—	—	—
Other Operating Expense	240	435	326	—	—	—
Operating Income	410	310	123	—	—	—
Interest Expense	30	28	44	—	—	—
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	3	3	23	—	—	—
Net Income Before Taxes	383	284	102	—	—	—
Income Taxes	113	93	46	—	—	—
Consolidated Net Income	269	192	56	—	—	—
Net Income From Continuing Operations	269	192	55	—	—	—
Net Income	269	192	56	—	—	—
EPS (Recurring)	1.70	1.23	0.38	—	—	—
EPS (Basic, Before Extraordinaries)	1.70	1.23	0.38	—	—	—
EPS (Diluted)	1.67	1.22	0.38	—	—	—
EBITDA	480	366	187	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	25.22	31.47	34.50	—	—	—
Price To Sales Ratio	1.20	1.13	0.47	—	—	—
Gross Margin	19.67	21.91	19.39	—	—	—
Operating Margin	7.39	5.86	3.01	—	—	—
Net Margin	4.85	3.63	1.37	—	—	—
Shares Outstanding	158	156	147	—	—	—
Market Capitalization	6,655	5,989	1,927	—	—	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jergensen Joshua	President & COO	Sep 16 '26	Sale	43.13	40,000	1,725,133	2,496,320	Sep 17
Hancock Mark	director, 10 percent owner:	Sep 15 '26	Sale	42.47	155,682	6,612,029	53,518,884	Sep 15
Hancock Mark	director, 10 percent owner:	Sep 14 '26	Sale	44.57	144,318	6,432,852	53,674,566	Sep 15
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 14 '26	Sale	45.03	317	14,275	54,555,249	Sep 14
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 11 '26	Sale	45.23	10,529	476,190	54,555,566	Sep 14
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 10 '26	Sale	45.16	8,771	396,105	54,566,095	Sep 14
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 09 '26	Sale	43.33	4,758	206,147	54,574,866	Sep 09
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 08 '26	Sale	43.49	24,057	1,046,327	54,579,624	Sep 09
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 04 '26	Sale	42.69	23,072	984,899	54,603,681	Sep 09
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 03 '26	Sale	42.56	20,173	858,483	54,626,753	Sep 03
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 02 '26	Sale	42.94	23,783	1,021,222	54,646,926	Sep 03
Murray Jason Hulse	Co-Founder, CEO & Chairman	Sep 01 '26	Sale	42.39	24,157	1,024,047	54,670,709	Sep 03
Conway Patrick Hugh	Director	Aug 14 '26	Sale	44.41	3,497	155,302	8,947	Aug 27
Murray Jason Hulse	Co-Founder, CEO & Chairman	Aug 21 '26	Sale	43.90	59,244	2,601,086	54,694,866	Aug 24
Murray Jason Hulse	Co-Founder, CEO & Chairman	Aug 20 '26	Sale	43.92	91,306	4,010,347	54,754,110	Aug 24

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.